Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Moderna (MRNA) Receives a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Decoding Moderna's Options Activity: What's the Big Picture?
Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
From Underperformance To Opportunity: Biotech's Case For 2025
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Yahoo Finance9d
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 candidate posted positive ...